سعر اتيكتورا بريزالر 150/320 مكجم 30 قرص 2026

Indacaterol 150 mcg / mometasone furoate 320 mcg inhalation powder hard capsules (LABA + inhaled corticosteroid for asthma), 30 capsules with Breezhaler inhaler, Novartis.

• Maintenance treatment of asthma not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.Population: Adults and adolescents 12 years of age and olderEuropean Medicines Agency (EPAR product information)

• Very common: asthma (exacerbation), nasopharyngitis. Common: upper respiratory tract infection, hypersensitivity, headache, oropharyngeal pain, dysphonia, musculoskeletal pain. Uncommon: candidiasis, angioedema, hyperglycaemia, blurred vision, cataract, tachycardia, rash, pruritus, muscle spasms.International label, same product · European Medicines Agency (EPAR product information)

• Hypersensitivity to the active substances or to any of the excipients.International label, same product · European Medicines Agency (EPAR product information)

• Not for the relief of acute bronchospasm or acute asthma symptoms; a short-acting bronchodilator should be available. Do not stop treatment abruptly; seek medical attention if asthma deteriorates.International label, same product · European Medicines Agency (EPAR product information)
• Immediate hypersensitivity reactions (including angioedema) and paradoxical bronchospasm may occur; discontinue immediately if they occur.International label, same product · European Medicines Agency (EPAR product information)
• Beta2-agonist effects: use with caution in cardiovascular disorders (coronary artery disease, acute MI, arrhythmias, hypertension), QT prolongation, convulsive disorders, thyrotoxicosis and in patients unusually responsive to beta2-agonists; hypokalaemia and hyperglycaemia may occur (monitor glucose in diabetes).International label, same product · European Medicines Agency (EPAR product information)

• Medicinal products known to prolong the QTc interval (e.g. MAO inhibitors, tricyclic antidepressants)May potentiate effects on the QT interval; use with caution.European Medicines Agency (EPAR product information)
• Hypokalaemic treatment (methylxanthine derivatives, steroids, non-potassium-sparing diuretics)May potentiate possible hypokalaemic effect of beta2-agonists; use with caution.European Medicines Agency (EPAR product information)
• Beta-adrenergic blockers (including eye drops)May weaken or antagonise the effect of beta2-agonists; avoid unless there are compelling reasons (cardioselective preferred, with caution).European Medicines Agency (EPAR product information)

• Insufficient data in pregnant women; use in pregnancy only if the expected benefit to the patient justifies the potential risk to the fetus. Beta2-agonists may inhibit labour through uterine smooth-muscle relaxation.International label, same product · European Medicines Agency (EPAR product information)
• Unknown whether indacaterol or mometasone are excreted in human milk (other inhaled corticosteroids are); decide whether to discontinue breastfeeding or therapy considering the benefit of breastfeeding for the child and of therapy for the woman.International label, same product · European Medicines Agency (EPAR product information)

• Indacaterol (as acetate): Partial agonist at the beta2-adrenergic receptor; increases cyclic AMP, relaxing bronchial smooth muscle; acts locally in the lung as a bronchodilator with rapid onset and long duration (EU SmPC).
• Mometasone furoate: Synthetic corticosteroid with high glucocorticoid-receptor affinity and local anti-inflammatory properties; inhibits leukotriene release and synthesis/release of IL-1, IL-5, IL-6 and TNF-alpha (EU SmPC).